Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Above 50 Day Moving Average – Should You Sell?

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $11.51 and traded as high as $12.47. Astria Therapeutics shares last traded at $11.87, with a volume of 356,408 shares traded.

Analyst Upgrades and Downgrades

ATXS has been the subject of a number of research reports. TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 target price for the company. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Friday, September 27th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Finally, Oppenheimer raised their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $25.20.

Astria Therapeutics Trading Up 3.1 %

The firm has a market capitalization of $669.76 million, a P/E ratio of -5.16 and a beta of 0.71. The stock has a 50-day simple moving average of $11.51 and a two-hundred day simple moving average of $10.53.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). As a group, research analysts expect that Astria Therapeutics, Inc. will post -1.68 EPS for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds have recently modified their holdings of the business. RA Capital Management L.P. bought a new position in Astria Therapeutics in the first quarter worth approximately $62,115,000. Vanguard Group Inc. raised its position in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in Astria Therapeutics by 15.4% during the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock valued at $8,878,000 after purchasing an additional 130,000 shares in the last quarter. Finally, Artal Group S.A. purchased a new position in Astria Therapeutics in the first quarter valued at about $12,445,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.